# A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy

> **NCT01144195** · PHASE2 · UNKNOWN · sponsor: **Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials** · enrollment: 80 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab + FOLFIRI

## Key facts

- **NCT ID:** NCT01144195
- **Lead sponsor:** Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-09
- **Primary completion:** 2011-12
- **Final completion:** —
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2010-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01144195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01144195, "A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01144195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*